Long-Term Effect of Acetyl-L-Carnitine for Antiretroviral Toxic Neuropathy
- 1 December 2005
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 6 (6) , 344-350
Abstract
Background: Nucleoside analogue reverse transcriptase inhibitors (NRTIs) used for the treatment of HIV can a cause distal symmetrical peripheral polyneuropathy by disruption of mitochondrial metabolism. Treatment with acetyl-L-carnitine (ALCAR) has shown short-term symptomatic and histological improvement. Long-term effects have not been investigated. Purpose: To assess the subjective and objective degree of antiretroviral toxic neuropathy (ATN) during treatment with ALCAR. Method: A cohort of 21 patients with ATN who commenced treatment with ALCAR between March 1999 and October 2001 was reviewed after a mean of 4.3 years using standardized questionnaires and neurological examination. Results: Of the 21 patients, 2 had died and 3 were lost to follow-up. 16 patients were assessed. 10 were still on potentially neurotoxic drugs. 13 were still taking ALCAR. 9 were pain free. The most common symptom was numbness (mild, moderate, and severe in 12, 3, and 0 patients, respectively), followed by paraesthesia (8, 2, 2), pain (4, 3, 0), and burning (5, 2, 0). There was mildly reduced sensation in the toes of 8 patients. 13 patients reported that ALCAR had improved their symptoms very much or moderately, 2 reported no change, and 1 reported a moderate worsening. Conclusion: ALCAR led to long-term symptomatic improvement in most patients without the need to discontinue neurotoxic drugs. Although in this study there was no control group, this agent appears to be an effective pathogenesis-based treatment for ATN.Keywords
This publication has 25 references indexed in Scilit:
- Acetyl-l-carnitineAIDS, 2004
- Self-care management for neuropathy in HIV diseaseAIDS Care, 2002
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Depletion of Cutaneous Peptidergic Innervation in HIV-Associated XerosisJournal of Investigative Dermatology, 1999
- Adverse effects of reverse transcriptase inhibitorsAIDS, 1998
- Peripheral Neuropathy with Nucleoside AntiretroviralsDrug Safety, 1998
- Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analoguesAIDS, 1997
- L-Acetylcarnitine in the Treatment of Patients with Peripheral NeuropathiesClinical Drug Investigation, 1995
- Acetyl-l-carnitine enhances the response of PC12 cells to nerve growth factorDevelopmental Brain Research, 1991
- Nerve growth factor binding in aged rat central nervous system: Effect of acetyl‐l‐carnitineJournal of Neuroscience Research, 1988